These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37311511)

  • 1. Leukapheresis and Tisagenlecleucel Manufacturing Outcomes in Patients Age <3 Years with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Fong D; Tiwari R; Acker C; Clough L; Willert J
    Transplant Cell Ther; 2023 Sep; 29(9):579.e1-579.e10. PubMed ID: 37311511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
    Tyagarajan S; Schmitt D; Acker C; Rutjens E
    Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing.
    Qayed M; McGuirk JP; Myers GD; Parameswaran V; Waller EK; Holman P; Rodrigues M; Clough LF; Willert J
    Cytotherapy; 2022 Sep; 24(9):869-878. PubMed ID: 35718701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective.
    Yang H; Hao Y; Qi CZ; Chai X; Wu EQ
    J Manag Care Spec Pharm; 2020 Aug; 26(8):971-980. PubMed ID: 32525730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
    Schultz LM; Baggott C; Prabhu S; Pacenta HL; Phillips CL; Rossoff J; Stefanski HE; Talano JA; Moskop A; Margossian SP; Verneris MR; Myers GD; Karras NA; Brown PA; Qayed M; Hermiston M; Satwani P; Krupski C; Keating AK; Wilcox R; Rabik CA; Fabrizio VA; Rouce RH; Chinnabhandar V; Kunicki M; Barsan VV; Goksenin AY; Li Y; Mavroukakis S; Egeler E; Curran KJ; Mackall CL; Laetsch TW
    J Clin Oncol; 2022 Mar; 40(9):945-955. PubMed ID: 34882493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection.
    Hall EM; Yin DE; Goyal RK; Ahmed AA; Mitchell GS; St Peter SD; Flatt TG; Ahmed IA; Li W; Hendrickson RJ; August KJ; Myers GD
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL.
    Korell F; Laier S; Sauer S; Veelken K; Hennemann H; Schubert ML; Sauer T; Pavel P; Mueller-Tidow C; Dreger P; Schmitt M; Schmitt A
    Cells; 2020 May; 9(5):. PubMed ID: 32429189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada.
    Furzer J; Gupta S; Nathan PC; Schechter T; Pole JD; Krueger J; Pechlivanoglou P
    JAMA Oncol; 2020 Mar; 6(3):393-401. PubMed ID: 31971547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study.
    Laetsch T; Zhang J; Yang H; Xie Y; Zhang D; Garrison L
    Appl Health Econ Health Policy; 2024 Sep; 22(5):749-765. PubMed ID: 38683438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan.
    Wakase S; Teshima T; Zhang J; Ma Q; Watanabe Y; Yang H; Qi CZ; Chai X; Xie Y; Wu EQ; Igarashi A
    Transplant Cell Ther; 2021 Mar; 27(3):241.e1-241.e11. PubMed ID: 33781519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study.
    Ghorashian S; Jacoby E; De Moerloose B; Rives S; Bonney D; Shenton G; Bader P; Bodmer N; Quintana AM; Herrero B; Algeri M; Locatelli F; Vettenranta K; Gonzalez B; Attarbaschi A; Harris S; Bourquin JP; Baruchel A
    Lancet Haematol; 2022 Oct; 9(10):e766-e775. PubMed ID: 36084658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Manufacturing results of tisagenlecleucel for acute lymphoblastic leukemia: a survey by the CAR-T cell therapy taskforce of the Japan Society of Transfusion Medicine and Cell Therapy].
    Jo T; Henzan T; Tomizawa D; Yoshihara S; Kahata K; Yamada-Fujiwara M; Okuyama Y; Shiba N; Fujii K; Umezawa Y; Yamazaki R; Takeda W; Hanajiri R; Fukushima K; Mimura N; Ikemoto J; Iwaki K; Yonetani N; Fujiwara SI; Ri M; Nagamura-Inoue T; Tanosaki R; Arai Y
    Rinsho Ketsueki; 2023; 64(5):331-337. PubMed ID: 37271521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC].
    Carnoy S; Beaumont JL; Kanouni T; Parquet N; Beauvais D; Hequet O; Kanold J; Ballot C; Mialou V; Reppel L; Damaj G; Yakoub-Agha I; Chabannon C
    Bull Cancer; 2021 Mar; 108(3):295-303. PubMed ID: 33610284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia.
    Vairy S; Garcia JL; Teira P; Bittencourt H
    Drug Des Devel Ther; 2018; 12():3885-3898. PubMed ID: 30518999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.
    Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
    JAMA Pediatr; 2018 Dec; 172(12):1161-1168. PubMed ID: 30304407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective.
    Yang H; Hao Y; Chai X; Qi CZ; Wu EQ
    J Med Econ; 2020 Sep; 23(9):1016-1024. PubMed ID: 32397772
    [No Abstract]   [Full Text] [Related]  

  • 17. Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia.
    Laetsch TW; Maude SL; Balduzzi A; Rives S; Bittencourt H; Boyer MW; Buechner J; De Moerloose B; Qayed M; Phillips CL; Pulsipher MA; Hiramatsu H; Tiwari R; Grupp SA
    Leukemia; 2022 Jun; 36(6):1508-1515. PubMed ID: 35422096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.
    Laetsch TW; Myers GD; Baruchel A; Dietz AC; Pulsipher MA; Bittencourt H; Buechner J; De Moerloose B; Davis KL; Nemecek E; Driscoll T; Mechinaud F; Boissel N; Rives S; Bader P; Peters C; Sabnis HS; Grupp SA; Yanik GA; Hiramatsu H; Stefanski HE; Rasouliyan L; Yi L; Shah S; Zhang J; Harris AC
    Lancet Oncol; 2019 Dec; 20(12):1710-1718. PubMed ID: 31606419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.
    Mueller KT; Waldron E; Grupp SA; Levine JE; Laetsch TW; Pulsipher MA; Boyer MW; August KJ; Hamilton J; Awasthi R; Stein AM; Sickert D; Chakraborty A; Levine BL; June CH; Tomassian L; Shah SS; Leung M; Taran T; Wood PA; Maude SL
    Clin Cancer Res; 2018 Dec; 24(24):6175-6184. PubMed ID: 30190371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Si Lim SJ; Grupp SA; DiNofia AM
    Pediatr Blood Cancer; 2021 Sep; 68(9):e29123. PubMed ID: 34061452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.